Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 31, 2013, Pages 12607-12612

  Sommese, Ruth F ^a   Sung, Jongmin ^a,b   Nag, Suman ^a   Sutton, Shirley ^a   Deacon, John C ^c   Choe, Elizabeth ^a,d   Leinwand, Leslie A ^c   Ruppel, Kathleen ^a   Spudich, James A ^a  

^a Department of Biochemistry ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart disease; Optical trapping; Single molecule force measurements

Indexed keywords

ADENOSINE TRIPHOSPHATASE; MYOSIN HEAVY CHAIN BETA; CARDIAC MYOSIN; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; EMBRYO; GENE MUTATION; GENETIC ASSOCIATION; HEART MUSCLE; HEART MUSCLE CONTRACTILE FORCE; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; MORBIDITY; MORTALITY; MOTOR PERFORMANCE; PRIORITY JOURNAL; VELOCITY; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; CARDIOMEGALY; CELL MOTION; GENETIC DISORDER; GENETICS; HEK293 CELL LINE; METABOLISM; MISSENSE MUTATION; MOUSE; OPTICAL TWEEZERS; PATHOLOGY;

AMINO ACID SUBSTITUTION; ANIMALS; CARDIAC MYOSINS; CARDIOMEGALY; CELL MOVEMENT; GENETIC DISEASES, INBORN; HEK293 CELLS; HUMANS; MICE; MUTATION, MISSENSE; MYOCARDIUM; MYOSIN HEAVY CHAINS; MYOSIN LIGHT CHAINS; OPTICAL TWEEZERS;

EID: 84881104951     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1309493110     Document Type: Article

References (35)

1. Maron BJ, et al. (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92(4): 785-789.
2. Ramaraj R (2008) Hypertrophic cardiomyopathy: Etiology, diagnosis, and treatment. Cardiol Rev 16(4):172-180.
3. Harvey PA, Leinwand LA (2011) The cell biology of disease: Cellular mechanisms of cardiomyopathy. J Cell Biol 194(3):355-365.
4. Geisterfer-Lowrance AA, et al. (1990) A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 62(5):999-1006.
5. Frey N, Luedde M, Katus HA (2012) Mechanisms of disease: Hypertrophic cardiomyopathy. Nat Rev Cardiol 9(2):91-100.
6. Moore JR, Leinwand L, Warshaw DM (2012) Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res 111(3):375-385.
7. Cuda G, Fananapazir L, Epstein ND, Sellers JR (1997) The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil 18(3):275-283.
8. Tyska MJ, et al. (2000) Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 86(7): 737-744.
9. Lowey S, et al. (2008) Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha-or beta-myosin heavy chain backbone. J Biol Chem 283(29):20579-20589.
10. Lowey S, Bretton V, Gulick J, Robbins J, Trybus KM (2013) Transgenic mouse alpha-and beta-cardiac myosins containing the R403Q mutation show isoform dependent transient kinetic differences. J Biol Chem 288(21):14780-14787, 10.1074/jbc.M113.450668.
11. Resnicow DI, Deacon JC, Warrick HM, Spudich JA, Leinwand LA (2010) Functional diversity among a family of human skeletal muscle myosin motors. Proc Natl Acad Sci USA 107(3):1053-1058.
12. Sata M, Ikebe M (1996) Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. J Clin Invest 98(12):2866-2873.
13. Palmer BM, et al. (2004) Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol 287(1):H91-H99.
14. Debold EP, et al. (2007) Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol 293(1):H284-H291.
15. Uyeda TQP, Kron SJ, Spudich JA (1990) Myosin step size. Estimation from slow sliding movement of actin over low densities of heavy meromyosin. J Mol Biol 214(3): 699-710.
16. De La Cruz EM, Ostap EM (2004) Relating biochemistry and function in the myosin superfamily. Curr Opin Cell Biol 16(1):61-67.
17. De La Cruz EM, Wells AL, Sweeney HL, Ostap EM (2000) Actin and light chain isoform dependence of myosin V kinetics. Biochemistry 39(46):14196-14202.
18. Greenberg MJ, Moore JR (2010) The molecular basis of frictional loads in the in vitro motility assay with applications to the study of the loaded mechanochemistry of molecular motors. Cytoskeleton (Hoboken) 67(5):273-285.
19. Janson LW, Sellers JR, Taylor DL (1992) Actin-binding proteins regulate the work performed by myosin II motors on single actin filaments. Cell Motil Cytoskeleton 22(4):274-280.
20. Fenn WO (1923) A quantitative comparison between the energy liberated and the work performed by the isolation sartorius muscle of the frog. J Physiol 58(2/3): 0175-0203.
21. Veigel C, Molloy JE, Schmitz S, Kendrick-Jones J (2003) Load-dependent kinetics of force production by smooth muscle myosin measured with optical tweezers. Nat Cell Biol 5(11):980-986.
22. Coureux PD, Sweeney HL, Houdusse A (2004) Three myosin V structures delineate essential features of chemo-mechanical transduction. EMBO J 23(23):4527-4537.
23. Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND (1993) Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest 91(6):2861-2865.
24. Wynne JBE (1992) The cardiomyopathies and myocarditis: Toxic, chemical and physical damage to the heart. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (Saunders, Philadelphia), pp 1394-1450.
25. Olivotto I, et al. (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106(2):261-267.
26. Ho CY, et al. (2002) Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105(25):2992-2997.
27. Deacon JC, Bloemink MJ, Rezavandi H, Geeves MA, Leinwand LA (2012) Identification of functional differences between recombinant human α and β cardiac myosin motors. Cell Mol Life Sci 69(13):2261-2277.
28. Pardee JD, Spudich JA (1982) Purification of muscle actin. Methods Enzymol 85(Pt B): 164-181.
29. Way M, Gooch J, Pope B, Weeds AG (1989) Expression of human plasma gelsolin in Escherichia coli and dissection of actin binding sites by segmental deletion mutagenesis. J Cell Biol 109(2):593-605.
30. Le Clainche C, Carlier MF (2004) Actin-based motility assay. Curr Protoc Cell Biol Chapter 12:Unit 12.7.
31. Feramisco JR, Burridge K (1980) A rapid purification of alpha-actinin, filamin, and a 130,000-dalton protein from smooth muscle. J Biol Chem 255(3):1194-1199.
32. Trybus KM (2000) Biochemical studies of myosin. Methods 22(4):327-335.
33. Kron SJ, Toyoshima YY, Uyeda TQ, Spudich JA (1991) Assays for actin sliding movement over myosin-coated surfaces. Methods Enzymol 196:399-416.
34. Bing W, Knott A, Marston SB (2000) A simple method for measuring the relative force exerted by myosin on actin filaments in the in vitro motility assay: Evidence that tropomyosin and troponin increase force in single thin filaments. Biochem J 350(Pt 3):693-699.
35. Berg-Sorensen K, Flyvbjerg H (2004) Power spectrum analysis for optical tweezers. Rev Sci Instrum 75(3):594-612.